These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

772 related items for PubMed ID: 7859456

  • 21. Alterations in endometrial stromal cell tissue factor protein and messenger ribonucleic acid expression in patients experiencing abnormal uterine bleeding while using Norplant-2 contraception.
    Runic R, Schatz F, Krey L, Demopoulos R, Thung S, Wan L, Lockwood CJ.
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1983-8. PubMed ID: 9177417
    [Abstract] [Full Text] [Related]

  • 22. Progesterone receptor in Norplant endometrium.
    Lau TM, Witjaksono J, Rogers PA.
    Hum Reprod; 1996 Oct; 11 Suppl 2():90-4. PubMed ID: 8982750
    [Abstract] [Full Text] [Related]

  • 23. Morphometric study of the human endometrium following continuous exposure to levonorgestrel released from vaginal rings during 90 days.
    Johannisson E, Brosens I, Cornillie F, Elder M, White J, Sheppard B, Hourihan H, d'Arcangues C, Belsey EM.
    Contraception; 1991 Apr; 43(4):361-74. PubMed ID: 1906792
    [Abstract] [Full Text] [Related]

  • 24. Intracervical and fundal administration of levonorgestrel for contraception: endometrial thickness, patterns of bleeding, and persisting ovarian follicles.
    Pakarinen PI, Suvisaari J, Luukkainen T, Lähteenmäki P.
    Fertil Steril; 1997 Jul; 68(1):59-64. PubMed ID: 9207585
    [Abstract] [Full Text] [Related]

  • 25. A five-year clinical evaluation of Norplant contraceptive subdermal implants in Bangladeshi acceptors.
    Akhter H, Dunson TR, Amatya RN, Begum K, Chowdhury T, Dighe N, Krueger SL, Rahman S.
    Contraception; 1993 Jun; 47(6):569-82. PubMed ID: 8334891
    [Abstract] [Full Text] [Related]

  • 26. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
    Faundes A, Brache V, Tejada AS, Cochon L, Alvarez-Sanchez F.
    Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
    [Abstract] [Full Text] [Related]

  • 27. Endometrial microvascular density during the normal menstrual cycle and following exposure to long-term levonorgestrel.
    Rogers PA, Au CL, Affandi B.
    Hum Reprod; 1993 Sep; 8(9):1396-404. PubMed ID: 8253925
    [Abstract] [Full Text] [Related]

  • 28. The effect of mefenamic acid on controlling irregular uterine bleeding secondary to Norplant use.
    Kaewrudee S, Taneepanichskul S, Jaisamraun U, Reinprayoon D.
    Contraception; 1999 Jul; 60(1):25-30. PubMed ID: 10549449
    [Abstract] [Full Text] [Related]

  • 29. A 2-year comparative study of endometrial histology and cervical cytology of contraceptive implant users in Birmingham, UK.
    Mascarenhas L, van Beek A, Bennink HC, Newton J.
    Hum Reprod; 1998 Nov; 13(11):3057-60. PubMed ID: 9853856
    [Abstract] [Full Text] [Related]

  • 30. Morphological and functional features of endometrial decidualization following long-term intrauterine levonorgestrel delivery.
    Critchley HO, Wang H, Jones RL, Kelly RW, Drudy TA, Gebbie AE, Buckley CH, McNeilly AS, Glasier AF.
    Hum Reprod; 1998 May; 13(5):1218-24. PubMed ID: 9647550
    [Abstract] [Full Text] [Related]

  • 31. Pharmacokinetic and pharmacodynamic investigations with vaginal devices releasing levonorgestrel at a constant, near zero order rate.
    Landgren BM, Johannisson E, Masironi B, Diczfalusy E.
    Contraception; 1982 Dec; 26(6):567-85. PubMed ID: 6820337
    [Abstract] [Full Text] [Related]

  • 32. The effects of levonorgestrel implants on vascular endothelial growth factor expression in the endometrium.
    Lau TM, Affandi B, Rogers PA.
    Mol Hum Reprod; 1999 Jan; 5(1):57-63. PubMed ID: 10050663
    [Abstract] [Full Text] [Related]

  • 33. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
    Xiao B, Zeng T, Wu S, Sun H, Xiao N.
    Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
    [Abstract] [Full Text] [Related]

  • 34. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives.
    Mainwaring R, Hales HA, Stevenson K, Hatasaka HH, Poulson AM, Jones KP, Peterson CM.
    Contraception; 1995 Mar; 51(3):149-53. PubMed ID: 7621683
    [Abstract] [Full Text] [Related]

  • 35. A review of the endometrial changes in Norplant users.
    Wan LS.
    Ann N Y Acad Sci; 1997 Sep 26; 828():108-10. PubMed ID: 9329828
    [Abstract] [Full Text] [Related]

  • 36. Endometrial vascular features prior to and following exposure to levonorgestrel.
    Hourihan HM, Sheppard BL, Belsey EM, Brosens IA.
    Contraception; 1991 Apr 26; 43(4):375-85. PubMed ID: 1906793
    [Abstract] [Full Text] [Related]

  • 37. Effectiveness of Norplant implants among Thai women in Bangkok.
    Chompootaweep S, Kochagarn E, Sirisumpan S, Tang-usaha J, Theppitaksak B, Dusitsin N.
    Contraception; 1996 Jan 26; 53(1):33-6. PubMed ID: 8631187
    [Abstract] [Full Text] [Related]

  • 38. Phase III clinical trial with Norplant II (two covered rods): report on five years of use.
    Contraception; 1993 Aug 26; 48(2):120-32. PubMed ID: 8403909
    [Abstract] [Full Text] [Related]

  • 39. Ovarian endocrine function through five years of continuous treatment with NORPLANT subdermal contraceptive implants.
    Brache V, Alvarez-Sanchez F, Faundes A, Tejada AS, Cochon L.
    Contraception; 1990 Feb 26; 41(2):169-77. PubMed ID: 2107058
    [Abstract] [Full Text] [Related]

  • 40. The effect of RU486 administered during the proliferative and secretory phase of the cycle on the bleeding pattern, hormonal parameters and the endometrium.
    Swahn ML, Johannisson E, Daniore V, de la Torre B, Bygdeman M.
    Hum Reprod; 1988 Oct 26; 3(7):915-21. PubMed ID: 2846630
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 39.